Drug Classifications and Pharmacologic Actions

Salvadora persica (SP) extract, displays very valuable biotherapeutic capacities such as antimicrobial, antioxidant, antiparasitic and anti-inflammatory effects. Numerous investigations have studied the pharmacologic actions of SP in oral disease therapies but its promising outcomes in periodontal health and treatment are not yet entirely described. The current study has been planned to analyze the reported effects of SP as a support to periodontal therapy to indorse regeneration and healing. In consort with clinical trials, in vitro investigations show the advantageous outcomes of SP adjunctive to periodontal treatment. Yet, comprehensive supplementary preclinical and clinical investigations at molecular and cellular levels are indispensable to reveal the exact therapeutic mechanisms of SP and its elements for periodontal health and therapy.

Download Full-text

The effect of N-methylation on fenfluramine's neurotoxic and pharmacologic actions

Brain Research ◽

10.1016/s0006-8993(97)00110-8 ◽

1997 ◽

Vol 763 (2) ◽

pp. 182-190 ◽

Cited By ~ 4

Author(s):

Jennifer Fasciano ◽

Thomas Steele ◽

Neal Castagnoli ◽

Jonathan Katz ◽

George Ricaurte

Keyword(s):

Pharmacologic Actions

Download Full-text

Pharmacologic actions of tetrodotoxin studied by direct perfusion of the sinus node

Toxicon ◽

10.1016/0041-0101(69)90172-x ◽

1969 ◽

Vol 7 (1) ◽

pp. 78

Author(s):

M.E.B.

Keyword(s):

Sinus Node ◽

Pharmacologic Actions

Download Full-text

Significance of Metformin Use in Diabetic Kidney Disease

International Journal of Molecular Sciences ◽

10.3390/ijms21124239 ◽

2020 ◽

Vol 21 (12) ◽

pp. 4239 ◽

Cited By ~ 2

Author(s):

Daiji Kawanami ◽

Yuichi Takashi ◽

Makito Tanabe

Keyword(s):

Kidney Disease ◽

Diabetic Kidney Disease ◽

Experimental Studies ◽

Glucose Lowering ◽

Diabetic Kidney ◽

First Line Therapy ◽

Stage Renal Disease ◽

End Stage ◽

Pharmacologic Actions

Metformin is a glucose-lowering agent that is used as a first-line therapy for type 2 diabetes (T2D). Based on its various pharmacologic actions, the renoprotective effects of metformin have been extensively studied. A series of experimental studies demonstrated that metformin attenuates diabetic kidney disease (DKD) by suppressing renal inflammation, oxidative stress and fibrosis. In clinical studies, metformin use has been shown to be associated with reduced rates of mortality, cardiovascular disease and progression to end-stage renal disease (ESRD) in T2D patients with chronic kidney disease (CKD). However, metformin should be administered with caution to patients with CKD because it may increase the risk of lactic acidosis. In this review article, we summarize our current understanding of the safety and efficacy of metformin for DKD.

Download Full-text